59908-47-3

Usage

Uses

Used in Pharmaceutical Industry:
5-CHLORO-1-METHYL-1H-INDOLE-2-CARBOXYLIC ACID is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and reactivity. Its presence in the molecular composition of drugs can contribute to their therapeutic effects and pharmacological properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-CHLORO-1-METHYL-1H-INDOLE-2-CARBOXYLIC ACID is utilized as a key component in the development of agrochemicals, potentially enhancing the effectiveness of pesticides, herbicides, and other agricultural products.
Used in Dye Production:
5-CHLORO-1-METHYL-1H-INDOLE-2-CARBOXYLIC ACID is used as an intermediate in the production of dyes, where its chemical properties can influence the color characteristics and stability of the resulting dyes.
Used in Organic Compounds Synthesis:
As a versatile intermediate, 5-CHLORO-1-METHYL-1H-INDOLE-2-CARBOXYLIC ACID is employed in the synthesis of a range of organic compounds for various applications, including but not limited to materials science, chemical research, and specialty chemicals manufacturing.
The potential applications of 5-CHLORO-1-METHYL-1H-INDOLE-2-CARBOXYLIC ACID are broad and diverse, reflecting its importance in the fields of chemistry and material science. Ongoing research continues to uncover new uses and refine existing ones, expanding the compound's relevance and utility.

Upstream product

• 587-04-2 m-Chlorobenzaldehyde 
• 4792-67-0 5-chloro-indole-2-carboxylic acid ethyl ester 
• 74-88-4 methyl iodide 
• 87802-11-7 methyl 5-chloroindole-2-carboxylate 
• 10517-21-2 5-chloro-1H-Indole-2-carboxylic acid 
• 148356-79-0 methyl 5-chloro-1-methyl-1H-indole-2-carboxylate 

Relevant academic research and scientific papers

Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor BI-4924 Disrupts Serine Biosynthesis

Phosphoglycerate dehydrogenase (PHGDH) is known to be the rate-limiting enzyme in the serine synthesis pathway in humans. It converts glycolysis-derived 3-phosphoglycerate to 3-phosphopyruvate in a co-factor-dependent oxidation reaction. Herein, we report the discovery of BI-4916, a prodrug of the co-factor nicotinamide adenine dinucleotide (NADH/NAD+)-competitive PHGDH inhibitor BI-4924, which has shown high selectivity against the majority of other dehydrogenase targets. Starting with a fragment-based screening, a subsequent hit optimization using structure-based drug design was conducted to deliver a single-digit nanomolar lead series and to improve potency by 6 orders of magnitude. To this end, an intracellular ester cleavage mechanism of the ester prodrug was utilized to achieve intracellular enrichment of the actual carboxylic acid based drug and thus overcome high cytosolic levels of the competitive cofactors NADH/NAD+

Flexibility of small molecular CD4 mimics as HIV entry inhibitors

CD4 mimics such as YIR-821 and its derivatives are small molecules which inhibit the interaction between the Phe43 cavity of HIV-1 gp120 with host CD4, an interaction that is involved in the entry of HIV to cells. Known CD4 mimics generally possess three

TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS

The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions

Structure-activity relationship study of β-oxidation resistant indole-based 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) receptor antagonists

5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is formed from 5S-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE) by the 5-lipoxygenase (5-LO) pathway under conditions associated with oxidative stress. 5-Oxo-ETE is an important pro-inflammatory mediator, which stimulates the migration of eosinophils via a selective G-protein coupled receptor, known as the OXE receptor (OXE-R). Previously, we designed and synthesized structural mimics of 5-oxo-ETE such as 1 using an indole scaffold. In the present work, we added various substituents at C-3 of this moiety to block potential β-oxidation of the 5-oxo-valerate side chain, and investigated the structure-activity relationships of the resulting novel β-oxidation-resistant antagonists. Cyclopropyl and cyclobutyl substituents were well tolerated in this position, but were less potent as the highly active 3S-methyl compound. It seems likely that 3-alkyl substituents can affect the conformation of the 5-oxovalerate side chain containing the critical keto and carboxyl groups, thereby affecting interaction with the OXE-receptor.

N-(piperidin-4-yl)-1H-indole-2-carboxamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Urotensin-Ⅱ receptor activity related diseases containing the same as an active ingredient

The present invention relates to N-(piperidin-4-yl)-1H-indole-2-carboxamide derivatives, a preparation method thereof, and a pharmaceutical composition for preventing or treating urotensin-II receptor activity-related diseases comprising the same as activ

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions and methods useful for treating a variety of diseases, disorders or conditions, associated with PHGDH.

COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY

The present invention relates to compounds that interact with ion channels. In particular, the invention relates to compounds having the structural Formula (I), (II), (III) or (IV), stereoisomers, tautomers, racemics, prodrugs, metabolites thereof, or a pharmaceutically acceptable salt and/or solvate thereof, Formula (I), (II), (III), (IV), wherein X1, X2, Y, Z, W, R1, R8 , R9, R10, L, A, z, and n have the meaning defined in claim 1. The invention also relates to methods for preparing said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods for treatment of the human and animal body.

Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them

The invention relates to a compound of formula in which R1, X1, X2, X3, X4, R4, Y1, Y2 and Y3 are as defined in claim 1. These compounds are CCK-receptor agonists.